Flumazenil intravenous（Expansion Therapeutics）

Product Name :
Flumazenil intravenous（Expansion Therapeutics）

Search keywords :
Flumazenil

drugId :
null

Target Vo:
Nucleotide-binding oligomerization domain-containing protein 2

Target Vo Short Name :
NOD2

Moa_Name:
Nucleotide-binding oligomerization domain-containing protein 2 antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Expansion Therapeutics Inc

Active Company_Name :
Expansion Therapeutics Inc

Active Indication_Name:
Myotonic Dystrophy

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Ku70 Rabbit mAb site
Calnexin Rabbit pAb site
FABP4 Antibody: FABP4 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 15 kDa, targeting to FABP4. It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts